HCG appoints Sanjeev Kumar as CFO, re-appoints director

1 min read     Updated on 26 May 2026, 08:48 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

HealthCare Global Enterprises Limited announced key leadership changes, including the appointment of Mr. Sanjeev Kumar as Chief Financial Officer effective May 25, 2026, replacing Interim CFO Dr. Manish Mattoo. The Board also re-appointed Mr. Rajiv Maliwal as a Non-Executive Independent Director for five years and Mr. Vijay S. Shanbhag as Internal Auditor for one year. Additionally, Mr. Ravi Gothwal was appointed as AVP – Investor Relations effective May 19, 2026.

powered bylight_fuzz_icon
40762799

*this image is generated using AI for illustrative purposes only.

HealthCare Global Enterprises Limited has strengthened its leadership team with the appointment of Mr. Sanjeev Kumar as Chief Financial Officer and Key Managerial Personnel effective May 25, 2026. The Board of Directors approved this appointment based on the recommendations of the Nomination and Remuneration Committee and the Audit Committee. Consequently, Dr. Manish Mattoo, Executive Director and Chief Executive Officer, ceased to hold the additional charge of Interim Chief Financial Officer from the same date. The company disclosed these changes to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leadership and Board Appointments

Alongside the CFO transition, the Board approved the re-appointment of Mr. Rajiv Maliwal as a Non-Executive Independent Director for a second term of five consecutive years effective from May 25, 2026, subject to shareholder approval. Mr. Maliwal is not liable to retire by rotation. Additionally, the Board appointed Mr. Ravi Gothwal as AVP – Investor Relations, designated as Senior Management Personnel, effective May 19, 2026.

Internal Auditor Re-appointment

The Board also re-appointed Mr. Vijay S. Shanbhag as the Internal Auditor for a further term of one year effective from May 30, 2026, under Section 138 of the Companies Act, 2013. The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 10:30 p.m.

Summary of Appointments

Name Designation Effective Date Term
Mr. Sanjeev Kumar Chief Financial Officer May 25, 2026 As per terms of employment
Mr. Rajiv Maliwal Non-Executive Independent Director May 25, 2026 5 years
Mr. Ravi Gothwal AVP – Investor Relations May 19, 2026 As per terms of employment
Mr. Vijay S. Shanbhag Internal Auditor May 30, 2026 1 year

What strategic financial priorities will Mr. Sanjeev Kumar likely pursue upon assuming the CFO role?

How will the market react to the re-appointment of Mr. Rajiv Maliwal given the requirement for shareholder approval?

What impact will the strengthened leadership team have on HealthCare Global's expansion plans?

HCG FY26 Revenue Rises 14% to INR 257,040 Mn

2 min read     Updated on 22 May 2026, 07:58 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

HealthCare Global Enterprises announced its audited FY26 results, reporting a 14% rise in total income to INR 257,040 Mn. Net profit attributable to equity holders stood at INR 1,376 Mn, while Adjusted PAT surged 25% to INR 557 Mn driven by operational efficiency. The company reduced net debt to INR 3,387 Mn and announced the divestment of its fertility business Milann for INR 376 Mn.

powered bylight_fuzz_icon
40763272

*this image is generated using AI for illustrative purposes only.

HealthCare Global Enterprises announced its audited annual financial results for the year ended March 31, 2026. The company reported a total income of INR 257,040 Mn for FY26, reflecting a 14% increase compared to INR 225,766 Mn in the previous fiscal year. The net profit for the period attributable to equity shareholders stood at INR 1,376 Mn, while the Adjusted Profit After Tax (PAT) for the full year surged to INR 557 Mn, a 25% increase from INR 444 Mn in FY25.

Operational and Financial Performance

The company's operational metrics showed robust expansion during the fiscal year. Volumes reached 294,912, a 12% increase from the prior year, while Average Realization Per Payor (ARPP) grew to INR 84,261. Adjusted EBITDA for the year stood at INR 4,711 Mn, a 19% year-over-year increase, with the margin expanding by 68 basis points to 18.5%. The West region emerged as a key growth driver, delivering 14% revenue growth, followed by the South and East regions with 13% and 11% growth respectively.

Q4 FY26 Highlights

In the fourth quarter, HealthCare Global Enterprises recorded total income of INR 66,540 Mn. The net profit attributable to equity shareholders for the quarter was INR 217 Mn. Adjusted EBITDA for the quarter increased by 17% to INR 1,252 Mn, with the margin expanding to 19.2% from 18.3% in the same period last year. The Adjusted PAT for the quarter surged to INR 341 Mn from INR 74 Mn in Q4 FY25. The company also recorded an exceptional item of INR 319 Mn in the current quarter.

Metric Q4 FY26 Q4 FY25 YoY Growth
Total Income (INR Mn) 66,540 59,539 12%
Adjusted EBITDA (INR Mn) 1,252 1,070 17%
Adjusted EBITDA Margin (%) 19.2% 18.3% +91 bps
Adjusted PAT (INR Mn) 341 74 363%
Net Profit Attributable (INR Mn) 217 736 -71%
Exceptional Item (INR Mn) 319

Strategic Developments

The Board approved the divestment of the company's non-core fertility business, Milann, to Inviga Healthcare Fund I. The transaction values Milann at an enterprise valuation of INR 632 Mn, with an equity consideration of INR 376 Mn payable in two tranches. The deal is expected to close in Q1 FY27, allowing the company to focus capital allocation on its core oncology platform.

Capital Allocation and Expansion

The company completed a rights issue to raise INR 4,250 Mn, which was oversubscribed 1.3 times. Capital expenditure for FY26 totaled INR 2,885 Mn, with significant investments directed towards the North Bangalore facility, which commenced operations bringing MR-LINAC technology to the region. Net debt as of March 31, 2026, stood at INR 3,387 Mn, a significant reduction from INR 6,317 Mn in the previous year, resulting in a net debt to EBITDA ratio of 0.98x.

Future Outlook

Management highlighted the company's path to improving profitability and return on capital, driven by the movement of centres into higher revenue buckets. The growing cohort of centres generating INR 50-100 Mn per month provides a strong foundation for future margin expansion. Additionally, brownfield expansion of over 200 beds is planned over the next 24 months across key locations including Bangalore, Cuttack, Ranchi, Vizag, and Bhavnagar.

How will the divestment of Milann to Inviga Healthcare Fund I impact HCG's ability to accelerate oncology-focused acquisitions or partnerships in FY27?

With net debt reduced to INR 3,387 Mn and a rights issue oversubscribed 1.3x, how might HCG deploy its strengthened balance sheet to compete against emerging oncology-focused hospital chains?

Given the MR-LINAC technology deployment in North Bangalore, what is the timeline for similar advanced technology rollouts across the planned 200+ bed brownfield expansion sites?

More News on Healthcare Global Enterprises